[1]
Cook A, Giunti P. Friedreich's ataxia: clinical features, pathogenesis and management. British medical bulletin. 2017 Dec 1:124(1):19-30. doi: 10.1093/bmb/ldx034. Epub
[PubMed PMID: 29053830]
[2]
Delatycki MB, Bidichandani SI. Friedreich ataxia- pathogenesis and implications for therapies. Neurobiology of disease. 2019 Dec:132():104606. doi: 10.1016/j.nbd.2019.104606. Epub 2019 Sep 5
[PubMed PMID: 31494282]
[3]
Lodi R, Tonon C, Calabrese V, Schapira AH. Friedreich's ataxia: from disease mechanisms to therapeutic interventions. Antioxidants & redox signaling. 2006 Mar-Apr:8(3-4):438-43
[PubMed PMID: 16677089]
[5]
Zhu D, Burke C, Leslie A, Nicholson GA. Friedreich's ataxia with chorea and myoclonus caused by a compound heterozygosity for a novel deletion and the trinucleotide GAA expansion. Movement disorders : official journal of the Movement Disorder Society. 2002 May:17(3):585-9
[PubMed PMID: 12112211]
[6]
Strawser CJ, Schadt KA, Lynch DR. Therapeutic approaches for the treatment of Friedreich's ataxia. Expert review of neurotherapeutics. 2014 Aug:14(8):949-57. doi: 10.1586/14737175.2014.939173. Epub 2014 Jul 18
[PubMed PMID: 25034024]
[7]
Strawser C, Schadt K, Hauser L, McCormick A, Wells M, Larkindale J, Lin H, Lynch DR. Pharmacological therapeutics in Friedreich ataxia: the present state. Expert review of neurotherapeutics. 2017 Sep:17(9):895-907. doi: 10.1080/14737175.2017.1356721. Epub 2017 Jul 26
[PubMed PMID: 28724340]
[8]
Aranca TV, Jones TM, Shaw JD, Staffetti JS, Ashizawa T, Kuo SH, Fogel BL, Wilmot GR, Perlman SL, Onyike CU, Ying SH, Zesiewicz TA. Emerging therapies in Friedreich's ataxia. Neurodegenerative disease management. 2016:6(1):49-65. doi: 10.2217/nmt.15.73. Epub
[PubMed PMID: 26782317]
[9]
Palau F. Friedreich's ataxia and frataxin: molecular genetics, evolution and pathogenesis (Review). International journal of molecular medicine. 2001 Jun:7(6):581-9
[PubMed PMID: 11351269]
[10]
Tanaka H. [Friedreich ataxia with GAA repeat expansion: molecular mechanism and clinical feature]. Nihon rinsho. Japanese journal of clinical medicine. 1999 Apr:57(4):960-6
[PubMed PMID: 10222797]
[11]
Lynch DR, Regner SR, Schadt KA, Friedman LS, Lin KY, St John Sutton MG. Management and therapy for cardiomyopathy in Friedreich's ataxia. Expert review of cardiovascular therapy. 2012 Jun:10(6):767-77. doi: 10.1586/erc.12.57. Epub
[PubMed PMID: 22894632]
[12]
Hanley A, Corrigan R, Mohammad S, MacMahon B. Friedreich's ataxia cardiomyopathy: case based discussion and management issues. Irish medical journal. 2010 Apr:103(4):117-8
[PubMed PMID: 20486316]
Level 3 (low-level) evidence
[13]
Bertoni PD, Canziani R, Cozzi G, Arancio F, Marforio S. [Cardiac involvement in Friedreich's heredo-ataxia]. Giornale italiano di cardiologia. 1986 Jan:16(1):22-9
[PubMed PMID: 2940141]
[14]
Weidemann F, Scholz F, Florescu C, Liu D, Hu K, Herrmann S, Ertl G, Störk S. [Heart involvement in Friedreich's ataxia]. Herz. 2015 Mar:40 Suppl 1():85-90. doi: 10.1007/s00059-014-4097-y. Epub 2014 May 23
[PubMed PMID: 24848865]
[15]
Lodi R, Rajagopalan B, Bradley JL, Taylor DJ, Crilley JG, Hart PE, Blamire AM, Manners D, Styles P, Schapira AH, Cooper JM. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives. Free radical research. 2002 Apr:36(4):461-6
[PubMed PMID: 12069111]
Level 3 (low-level) evidence
[16]
Bit-Avragim N, Perrot A, Schöls L, Hardt C, Kreuz FR, Zühlke C, Bubel S, Laccone F, Vogel HP, Dietz R, Osterziel KJ. The GAA repeat expansion in intron 1 of the frataxin gene is related to the severity of cardiac manifestation in patients with Friedreich's ataxia. Journal of molecular medicine (Berlin, Germany). 2001:78(11):626-32
[PubMed PMID: 11269509]
[17]
Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Cañizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel JL, Cocozza S, Koenig M, Pandolfo M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (New York, N.Y.). 1996 Mar 8:271(5254):1423-7
[PubMed PMID: 8596916]
[18]
Hebert MD, Whittom AA. Gene-based approaches toward Friedreich ataxia therapeutics. Cellular and molecular life sciences : CMLS. 2007 Dec:64(23):3034-43
[PubMed PMID: 17828464]
[19]
Zühlke CH, Dalski A, Habeck M, Straube K, Hedrich K, Hoeltzenbein M, Konstanzer A, Hellenbroich Y, Schwinger E. Extension of the mutation spectrum in Friedreich's ataxia: detection of an exon deletion and novel missense mutations. European journal of human genetics : EJHG. 2004 Nov:12(11):979-82
[PubMed PMID: 15340363]
[20]
Bartolo C, Mendell JR, Prior TW. Identification of a missense mutation in a Friedreich's ataxia patient: implications for diagnosis and carrier studies. American journal of medical genetics. 1998 Oct 12:79(5):396-9
[PubMed PMID: 9779809]
[21]
Cossée M,Dürr A,Schmitt M,Dahl N,Trouillas P,Allinson P,Kostrzewa M,Nivelon-Chevallier A,Gustavson KH,Kohlschütter A,Müller U,Mandel JL,Brice A,Koenig M,Cavalcanti F,Tammaro A,De Michele G,Filla A,Cocozza S,Labuda M,Montermini L,Poirier J,Pandolfo M, Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Annals of neurology. 1999 Feb;
[PubMed PMID: 9989622]
[22]
Kellett MW, Fletcher NA, Wood N, Enevoldson TP. Trinucleotide (GAA)n repeat expansion in two families with Friedreich's ataxia with retained reflexes. Journal of neurology, neurosurgery, and psychiatry. 1997 Dec:63(6):780-3
[PubMed PMID: 9416816]
[23]
Lucotte G, Berriche S, David F, Bathelier C, Turpin JC. Trinucleotide GAA repeat expansions in seven French Friedreich ataxia families. Genetic counseling (Geneva, Switzerland). 1997:8(3):189-94
[PubMed PMID: 9327260]
[24]
Rao VK, DiDonato CJ, Larsen PD. Friedreich's Ataxia: Clinical Presentation of a Compound Heterozygote Child with a Rare Nonsense Mutation and Comparison with Previously Published Cases. Case reports in neurological medicine. 2018:2018():8587203. doi: 10.1155/2018/8587203. Epub 2018 Aug 9
[PubMed PMID: 30159187]
Level 3 (low-level) evidence
[25]
Yilmaz MB, Koç AF, Kasap H, Güzel AI, Sarica Y, Süleymanova D. GAA repeat polymorphism in Turkish Friedreich's ataxia patients. The International journal of neuroscience. 2006 May:116(5):565-74
[PubMed PMID: 16644517]
[26]
Houshmand M, Panahi MS, Nafisi S, Soltanzadeh A, Alkandari FM. Identification and sizing of GAA trinucleotide repeat expansion, investigation for D-loop variations and mitochondrial deletions in Iranian patients with Friedreich's ataxia. Mitochondrion. 2006 Apr:6(2):82-8
[PubMed PMID: 16581313]
[27]
Martelli A, Puccio H. Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation. Frontiers in pharmacology. 2014:5():130. doi: 10.3389/fphar.2014.00130. Epub 2014 Jun 3
[PubMed PMID: 24917819]
[28]
Rötig A, Sidi D, Munnich A, Rustin P. Molecular insights into Friedreich's ataxia and antioxidant-based therapies. Trends in molecular medicine. 2002 May:8(5):221-4
[PubMed PMID: 12067631]
[29]
Rötig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, Rustin P. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nature genetics. 1997 Oct:17(2):215-7
[PubMed PMID: 9326946]
[30]
Koeppen AH, Becker AB, Qian J, Feustel PJ. Friedreich Ataxia: Hypoplasia of Spinal Cord and Dorsal Root Ganglia. Journal of neuropathology and experimental neurology. 2017 Feb 1:76(2):101-108. doi: 10.1093/jnen/nlw111. Epub
[PubMed PMID: 28082326]
Level 2 (mid-level) evidence
[31]
Morral JA, Davis AN, Qian J, Gelman BB, Koeppen AH. Pathology and pathogenesis of sensory neuropathy in Friedreich's ataxia. Acta neuropathologica. 2010 Jul:120(1):97-108. doi: 10.1007/s00401-010-0675-0. Epub 2010 Mar 26
[PubMed PMID: 20339857]
Level 2 (mid-level) evidence
[32]
Koeppen AH, Morral JA, Davis AN, Qian J, Petrocine SV, Knutson MD, Gibson WM, Cusack MJ, Li D. The dorsal root ganglion in Friedreich's ataxia. Acta neuropathologica. 2009 Dec:118(6):763-76. doi: 10.1007/s00401-009-0589-x. Epub 2009 Aug 30
[PubMed PMID: 19727777]
Level 2 (mid-level) evidence
[33]
Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. Journal of neuropathology and experimental neurology. 2013 Feb:72(2):78-90. doi: 10.1097/NEN.0b013e31827e5762. Epub
[PubMed PMID: 23334592]
[34]
Koeppen AH. Nikolaus Friedreich and degenerative atrophy of the dorsal columns of the spinal cord. Journal of neurochemistry. 2013 Aug:126 Suppl 1(0 1):4-10. doi: 10.1111/jnc.12218. Epub
[PubMed PMID: 23859337]
[35]
Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. Journal of the neurological sciences. 2011 Apr 15:303(1-2):1-12. doi: 10.1016/j.jns.2011.01.010. Epub
[PubMed PMID: 21315377]
[36]
Koeppen AH, Morral JA, McComb RD, Feustel PJ. The neuropathology of late-onset Friedreich's ataxia. Cerebellum (London, England). 2011 Mar:10(1):96-103. doi: 10.1007/s12311-010-0235-0. Epub
[PubMed PMID: 21128039]
[37]
Wood AH, Dubrey SW. Cardiomyopathy and the electrocardiogram in Friedreich's ataxia. British journal of hospital medicine (London, England : 2005). 2013 Apr:74(4):232-3
[PubMed PMID: 23571398]
[38]
Dutka DP, Donnelly JE, Nihoyannopoulos P, Oakley CM, Nunez DJ. Marked variation in the cardiomyopathy associated with Friedreich's ataxia. Heart (British Cardiac Society). 1999 Feb:81(2):141-7
[PubMed PMID: 9922348]
[39]
Milne SC, Corben LA, Roberts M, Murphy A, Tai G, Georgiou-Karistianis N, Yiu EM, Delatycki MB. Can rehabilitation improve the health and well-being in Friedreich's ataxia: a randomized controlled trial? Clinical rehabilitation. 2018 May:32(5):630-643. doi: 10.1177/0269215517736903. Epub 2017 Oct 26
[PubMed PMID: 29072092]
Level 1 (high-level) evidence
[40]
Bonnechère B, Jansen B, Haack I, Omelina L, Feipel V, Van Sint Jan S, Pandolfo M. Automated functional upper limb evaluation of patients with Friedreich ataxia using serious games rehabilitation exercises. Journal of neuroengineering and rehabilitation. 2018 Oct 4:15(1):87. doi: 10.1186/s12984-018-0430-7. Epub 2018 Oct 4
[PubMed PMID: 30286776]
[41]
Maring JR, Croarkin E. Presentation and progression of Friedreich ataxia and implications for physical therapist examination. Physical therapy. 2007 Dec:87(12):1687-96
[PubMed PMID: 17911272]
[42]
Sedlak TL, Chandavimol M, Straatman L. Cardiac transplantation: a temporary solution for Friedreich's ataxia-induced dilated cardiomyopathy. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2004 Nov:23(11):1304-6
[PubMed PMID: 15539131]
[43]
Musova Z, Sedlacek Z, Mazanec R, Klempir J, Roth J, Plevova P, Vyhnalek M, Kopeckova M, Apltova L, Krepelova A, Zumrova A. Spinocerebellar ataxias type 8, 12, and 17 and dentatorubro-pallidoluysian atrophy in Czech ataxic patients. Cerebellum (London, England). 2013 Apr:12(2):155-61. doi: 10.1007/s12311-012-0403-5. Epub
[PubMed PMID: 22872568]
[44]
Li H, Hu X, Fei L, Zhang P, Chen X, Ouyang M, Zhang W, Liu X. [Clinical and genetic characteristics of patients with dentatorubro-pallidoluysian atrophy]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics. 2016 Oct:33(5):610-4. doi: 10.3760/cma.j.issn.1003-9406.2016.05.006. Epub
[PubMed PMID: 27577205]
[45]
Lewis RA. Chronic inflammatory demyelinating polyneuropathy. Current opinion in neurology. 2017 Oct:30(5):508-512. doi: 10.1097/WCO.0000000000000481. Epub
[PubMed PMID: 28763304]
Level 3 (low-level) evidence
[46]
Kuwabara S, Misawa S. Chronic Inflammatory Demyelinating Polyneuropathy. Advances in experimental medicine and biology. 2019:1190():333-343. doi: 10.1007/978-981-32-9636-7_21. Epub
[PubMed PMID: 31760654]
Level 3 (low-level) evidence
[47]
Lehmann HC, Burke D, Kuwabara S. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. Journal of neurology, neurosurgery, and psychiatry. 2019 Sep:90(9):981-987. doi: 10.1136/jnnp-2019-320314. Epub 2019 Apr 16
[PubMed PMID: 30992333]
[48]
Koehler PJ. Gabrielle Lévy and the Roussy-Lévy syndrome. Journal of the history of the neurosciences. 2018 Apr-Jun:27(2):117-144. doi: 10.1080/0964704X.2018.1423848. Epub 2018 Feb 22
[PubMed PMID: 29469679]
[49]
Bartosik-Psujek H, Stelmasiak Z. A case of the Roussy-Levy syndrome family. Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina. 2001:56():393-5
[PubMed PMID: 11977346]
Level 3 (low-level) evidence
[50]
Roenn CP, Li M, Schack VR, Forster IC, Holm R, Toustrup-Jensen MS, Andersen JP, Petrou S, Vilsen B. Functional consequences of the CAPOS mutation E818K of Na(+),K(+)-ATPase. The Journal of biological chemistry. 2019 Jan 4:294(1):269-280. doi: 10.1074/jbc.RA118.004591. Epub 2018 Nov 8
[PubMed PMID: 30409907]
[51]
Jen JC, Wan J. Episodic ataxias. Handbook of clinical neurology. 2018:155():205-215. doi: 10.1016/B978-0-444-64189-2.00013-5. Epub
[PubMed PMID: 29891059]
[52]
Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Hasan SM, D'Adamo MC. Episodic Ataxia Type 1. GeneReviews(®). 1993:():
[PubMed PMID: 20301785]
[53]
Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Spacey S. Episodic Ataxia Type 2 – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY. GeneReviews(®). 1993:():
[PubMed PMID: 20301674]
[54]
Synofzik M, Németh AH. Recessive ataxias. Handbook of clinical neurology. 2018:155():73-89. doi: 10.1016/B978-0-444-64189-2.00005-6. Epub
[PubMed PMID: 29891078]
[55]
Briand MM, Rodrigue X, Lessard I, Mathieu J, Brais B, Côté I, Gagnon C. Expanding the clinical description of autosomal recessive spastic ataxia of Charlevoix-Saguenay. Journal of the neurological sciences. 2019 May 15:400():39-41. doi: 10.1016/j.jns.2019.03.008. Epub 2019 Mar 12
[PubMed PMID: 30901567]
[56]
Hernandez-Diaz S, Soukup SF. The role of lipids in autophagy and its implication in neurodegeneration. Cell stress. 2020 May 19:4(7):167-186. doi: 10.15698/cst2020.07.225. Epub 2020 May 19
[PubMed PMID: 32656499]
[57]
van Gaalen J, Kerstens FG, Maas RP, Härmark L, van de Warrenburg BP. Drug-induced cerebellar ataxia: a systematic review. CNS drugs. 2014 Dec:28(12):1139-53. doi: 10.1007/s40263-014-0200-4. Epub
[PubMed PMID: 25391707]
Level 1 (high-level) evidence
[58]
Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Schuelke M. Ataxia with Vitamin E Deficiency. GeneReviews(®). 1993:():
[PubMed PMID: 20301419]
[59]
Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet journal of rare diseases. 2016 Nov 25:11(1):159
[PubMed PMID: 27884168]
[61]
Wanders RJ, Jansen GA, Skjeldal OH. Refsum disease, peroxisomes and phytanic acid oxidation: a review. Journal of neuropathology and experimental neurology. 2001 Nov:60(11):1021-31
[PubMed PMID: 11706932]
[62]
Pallardó FV, Pagano G, Rodríguez LR, Gonzalez-Cabo P, Lyakhovich A, Trifuoggi M. Friedreich Ataxia: current state-of-the-art, and future prospects for mitochondrial-focused therapies. Translational research : the journal of laboratory and clinical medicine. 2021 Mar:229():135-141. doi: 10.1016/j.trsl.2020.08.009. Epub 2020 Aug 22
[PubMed PMID: 32841735]
[63]
Clay A, Hearle P, Schadt K, Lynch DR. New developments in pharmacotherapy for Friedreich ataxia. Expert opinion on pharmacotherapy. 2019 Oct:20(15):1855-1867. doi: 10.1080/14656566.2019.1639671. Epub 2019 Jul 16
[PubMed PMID: 31311349]
Level 3 (low-level) evidence
[64]
Lynch DR, Hauser L, McCormick A, Wells M, Dong YN, McCormack S, Schadt K, Perlman S, Subramony SH, Mathews KD, Brocht A, Ball J, Perdok R, Grahn A, Vescio T, Sherman JW, Farmer JM. Randomized, double-blind, placebo-controlled study of interferon-γ 1b in Friedreich Ataxia. Annals of clinical and translational neurology. 2019 Mar:6(3):546-553. doi: 10.1002/acn3.731. Epub 2019 Feb 27
[PubMed PMID: 30911578]
Level 1 (high-level) evidence
[65]
Nuñez MT, Chana-Cuevas P. New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases. Pharmaceuticals (Basel, Switzerland). 2018 Oct 19:11(4):. doi: 10.3390/ph11040109. Epub 2018 Oct 19
[PubMed PMID: 30347635]
Level 3 (low-level) evidence
[66]
Zesiewicz T, Salemi JL, Perlman S, Sullivan KL, Shaw JD, Huang Y, Isaacs C, Gooch C, Lynch DR, Klein MB. Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia. Neurodegenerative disease management. 2018 Aug:8(4):233-242. doi: 10.2217/nmt-2018-0013. Epub 2018 Jul 27
[PubMed PMID: 30051753]
Level 1 (high-level) evidence
[67]
Zesiewicz T, Heerinckx F, De Jager R, Omidvar O, Kilpatrick M, Shaw J, Shchepinov MS. Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia. Movement disorders : official journal of the Movement Disorder Society. 2018 Jul:33(6):1000-1005. doi: 10.1002/mds.27353. Epub 2018 Apr 6
[PubMed PMID: 29624723]
Level 1 (high-level) evidence
[68]
Carletti B, Piemonte F. Friedreich's Ataxia: A Neuronal Point of View on the Oxidative Stress Hypothesis. Antioxidants (Basel, Switzerland). 2014 Sep 10:3(3):592-603. doi: 10.3390/antiox3030592. Epub 2014 Sep 10
[PubMed PMID: 26785073]
[69]
Polak U, Li Y, Butler JS, Napierala M. Alleviating GAA Repeat Induced Transcriptional Silencing of the Friedreich's Ataxia Gene During Somatic Cell Reprogramming. Stem cells and development. 2016 Dec 1:25(23):1788-1800
[PubMed PMID: 27615158]
[70]
Abeti R, Baccaro A, Esteras N, Giunti P. Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich's Ataxia Models. Frontiers in cellular neuroscience. 2018:12():188. doi: 10.3389/fncel.2018.00188. Epub 2018 Jul 17
[PubMed PMID: 30065630]
[71]
Soriano S, Llorens JV, Blanco-Sobero L, Gutiérrez L, Calap-Quintana P, Morales MP, Moltó MD, Martínez-Sebastián MJ. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia. Gene. 2013 Jun 1:521(2):274-81. doi: 10.1016/j.gene.2013.02.049. Epub 2013 Mar 28
[PubMed PMID: 23542074]
[72]
Arpa J, Sanz-Gallego I, Rodríguez-de-Rivera FJ, Domínguez-Melcón FJ, Prefasi D, Oliva-Navarro J, Moreno-Yangüela M. Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia - open-label trial. Acta neurologica Scandinavica. 2014 Jan:129(1):32-40. doi: 10.1111/ane.12141. Epub 2013 May 14
[PubMed PMID: 23668357]
[73]
Cooper JM, Schapira AH. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy. BioFactors (Oxford, England). 2003:18(1-4):163-71
[PubMed PMID: 14695932]
[74]
Cooper JM, Schapira AH. Friedreich's ataxia: coenzyme Q10 and vitamin E therapy. Mitochondrion. 2007 Jun:7 Suppl():S127-35
[PubMed PMID: 17485244]
[75]
Mollá B,Muñoz-Lasso DC,Calap P,Fernandez-Vilata A,de la Iglesia-Vaya M,Pallardó FV,Moltó MD,Palau F,Gonzalez-Cabo P, Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich's Ataxia Mouse Model. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2019 Apr;
[PubMed PMID: 30761510]
[76]
Trouillas P, Takayanagi T, Hallett M, Currier RD, Subramony SH, Wessel K, Bryer A, Diener HC, Massaquoi S, Gomez CM, Coutinho P, Ben Hamida M, Campanella G, Filla A, Schut L, Timann D, Honnorat J, Nighoghossian N, Manyam B. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. Journal of the neurological sciences. 1997 Feb 12:145(2):205-11
[PubMed PMID: 9094050]
[77]
Subramony SH, May W, Lynch D, Gomez C, Fischbeck K, Hallett M, Taylor P, Wilson R, Ashizawa T, Cooperative Ataxia Group. Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. Neurology. 2005 Apr 12:64(7):1261-2
[PubMed PMID: 15824358]
[78]
Fahey MC, Corben L, Collins V, Churchyard AJ, Delatycki MB. How is disease progress in Friedreich's ataxia best measured? A study of four rating scales. Journal of neurology, neurosurgery, and psychiatry. 2007 Apr:78(4):411-3
[PubMed PMID: 17056635]
[79]
Schwabova J, Maly T, Laczo J, Zumrova A, Komarek V, Musova Z, Zahalka F. Application of a Scale for the Assessment and Rating of Ataxia (SARA) in Friedreich's ataxia patients according to posturography is limited. Journal of the neurological sciences. 2014 Jun 15:341(1-2):64-7. doi: 10.1016/j.jns.2014.04.001. Epub 2014 Apr 12
[PubMed PMID: 24768059]
[80]
Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, Ravina B, Koeppen AH, Lynch DR. Mortality in Friedreich ataxia. Journal of the neurological sciences. 2011 Aug 15:307(1-2):46-9. doi: 10.1016/j.jns.2011.05.023. Epub 2011 Jun 8
[PubMed PMID: 21652007]
[81]
Hawley RJ, Gottdiener JS. Five-year follow-up of Friedreich's ataxia cardiomyopathy. Archives of internal medicine. 1986 Mar:146(3):483-8
[PubMed PMID: 3954519]